ArticleCureus2026
Localized Facial Bullous Eruption Following Iodinated Contrast in a Patient With Renal Failure.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iodinated contrast media (ICM) can induce delayed hypersensitivity reactions, but localized recurrent bullous eruptions are exceedingly rare. We present the case of a 51-year-old male with end-stage renal disease (ESRD) who developed a recurrent, highly localized bullous facial dermatosis following repeated intravenous ICM administration for vascular interventions. His initial reaction of diffuse facial flushing evolved with subsequent exposures into severe, anatomically fixed facial blistering that strictly spared the oral mucosa, ultimately resolving into profound post-inflammatory hyperpigmentation. This case presents a unique diagnostic overlap: the strict anatomic recurrence represents the clinical hallmark of a fixed drug eruption, while the severity of the blistering in the setting of ESRD suggests a synergistic toxicokinetic mechanism akin to iododerma. The patient's profound renal impairment likely caused delayed contrast clearance, resulting in a massive systemic iodine load that amplified the hapten-driven localized inflammatory response. Clinicians must recognize evolving hypersensitivity patterns to ICM, as delayed clearance in renal dysfunction can drastically exacerbate localized T-cell-mediated cutaneous reactions, leading to severe dyspigmentation if the offending agent is not promptly identified and avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.